Transport
Central Iowa Hospital Corporation
Central Iowa Hospital Corporation was paid $58.07M by Medicaid between Jan 2018 and Dec 2024, across 170 billing codes. Its largest line is 99284, emergency room visit (serious) — 30% of everything it billed.
33Billing provider infoCENTRAL IOWA HOSPITAL CORPORATION
DES MOINES, IA 50309
DES MOINES, IA 50309
33aNPI1396837951assigned 09/29/2006
33bProvider typeAmbulance
28Total paid$58.07M
24GClaims692,046
24DCodes billed170
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulance providers in Iowa
Rank by total paid#2 of 45
Median peer was paid$85K
This provider vs. median681×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ALLEN, PATRICIA controls 18+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 78,174 | $6.43M | |
| 2019 | 78,750 | $6.47M | |
| 2020 | 63,116 | $4.95M | |
| 2021 | 110,854 | $9.80M | |
| 2022 | 146,024 | $12.61M | |
| 2023 | 137,568 | $10.93M | |
| 2024incomplete | 77,560 | $6.88M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 58,762 | 56,311 | $17.24M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 20% | 103,996 | 98,213 | $11.45M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 18% | 26,732 | 25,216 | $10.43M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10.0% | 30,765 | 29,662 | $5.79M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3.2% | 138,325 | 132,093 | $1.88M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.0% | 11,553 | 10,742 | $1.72M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 2.3% | 4,148 | 4,034 | $1.36M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 1.2% | 15,026 | 14,542 | $700K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 1.2% | 1,492 | 728 | $672K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.1% | 8,212 | 7,981 | $618K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,323 | 4,185 | $518K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 9,587 | 3,812 | $506K |
158 more codes
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 6,198 | $468K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 6,827 | $467K |
| J0485 | Injection, belatacept, 1 mg | <1% | 964 | $425K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,665 | $314K |
| S9455 | Diabetic management program, group session | <1% | 2,486 | $311K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 962 | $286K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 4,409 | $272K |
| 90461 | <1% | 6,799 | $249K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 3,408 | $226K |
| 59025 | Fetal non-stress test | <1% | 1,719 | $214K |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 3,939 | $185K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 282 | $182K |
| 90670 | <1% | 2,688 | $113K | |
| 64615 | <1% | 716 | $113K | |
| 95813 | <1% | 511 | $113K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,642 | $103K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,456 | $92K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,052 | $84K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 11,154 | $84K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 561 | $63K |
| 90686 | <1% | 7,397 | $62K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 680 | $57K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 44,351 | $49K |
| 97597 | <1% | 561 | $47K | |
| 80053 | Comprehensive metabolic panel | <1% | 24,042 | $46K |
| 96127 | <1% | 10,983 | $45K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 196 | $34K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 637 | $34K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,144 | $33K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,376 | $32K |
| 94060 | <1% | 110 | $31K | |
| 93296 | <1% | 1,492 | $29K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 273 | $25K |
| 90723 | <1% | 1,033 | $19K | |
| 0072A | <1% | 515 | $19K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 180 | $18K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 134 | $18K |
| 0071A | <1% | 461 | $16K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 131 | $15K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 83 | $15K |
| 91200 | <1% | 121 | $13K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 81 | $12K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 353 | $11K |
| 94010 | <1% | 2,567 | $11K | |
| 97803 | <1% | 552 | $10K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 398 | $10K |
| 91321 | <1% | 113 | $9K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 57 | $8K |
| 85046 | <1% | 1,422 | $7K | |
| 95913 | <1% | 20 | $7K | |
| 90651 | <1% | 91 | $7K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 46,421 | $6K |
| 82728 | <1% | 445 | $5K | |
| 83690 | <1% | 4,932 | $5K | |
| 81001 | <1% | 16,584 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 94 | $5K |
| 92523 | <1% | 30 | $5K | |
| 92526 | <1% | 63 | $4K | |
| 90677 | <1% | 125 | $4K | |
| 94762 | <1% | 30 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,775 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,353 | $3K |
| 97802 | <1% | 61 | $2K | |
| 81025 | <1% | 1,486 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,380 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 164 | $1K |
| 0154A | <1% | 49 | $1K | |
| 29581 | <1% | 25 | $1K | |
| 93017 | <1% | 57 | $1K | |
| 0082A | <1% | 41 | $1K | |
| 91322 | <1% | 12 | $1K | |
| 90672 | <1% | 153 | $939.55 | |
| G0008 | Administration of influenza virus vaccine | <1% | 31 | $937.18 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 62 | $887.12 |
| 99173 | <1% | 608 | $763.39 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,171 | $593.26 |
| 90697 | <1% | 195 | $576.89 | |
| 0074A | <1% | 21 | $560.00 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 15 | $542.76 |
| J2704 | Injection, propofol, 10 mg | <1% | 86 | $518.51 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 456 | $332.90 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 913 | $279.21 |
| 90734 | <1% | 12 | $273.39 | |
| 99177 | <1% | 447 | $257.92 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 302 | $232.77 |
| J3490 | Unclassified drugs | <1% | 47 | $221.94 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 471 | $219.80 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 42 | $125.00 |
| 85652 | <1% | 54 | $123.71 | |
| 69210 | <1% | 17 | $111.88 | |
| 83550 | <1% | 17 | $107.90 | |
| 83735 | <1% | 912 | $105.84 | |
| 74019 | <1% | 391 | $103.43 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 13 | $88.99 |
| 83540 | <1% | 17 | $79.95 | |
| 84100 | <1% | 16 | $72.86 | |
| 84484 | <1% | 3,343 | $69.91 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 434 | $69.08 |
| 82962 | <1% | 192 | $40.56 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 184 | $35.15 |
| 83605 | <1% | 154 | $31.54 | |
| 85027 | <1% | 342 | $30.33 | |
| 81003 | <1% | 556 | $22.42 | |
| 87510 | <1% | 73 | $19.05 | |
| 87480 | <1% | 73 | $19.05 | |
| 87660 | <1% | 73 | $19.05 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 516 | $17.78 |
| 82077 | <1% | 27 | $16.41 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 28 | $15.72 |
| 87081 | <1% | 325 | $13.94 | |
| 80047 | <1% | 456 | $13.71 | |
| 87430 | <1% | 620 | $10.40 | |
| 85610 | <1% | 73 | $8.16 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 24 | $4.89 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 14 | $3.43 |
| 85014 | <1% | 453 | $2.93 | |
| 95886 | 0% | 258 | $0.00 | |
| 90680 | 0% | 1,135 | $0.00 | |
| 95012 | 0% | 711 | $0.00 | |
| 90647 | 0% | 1,123 | $0.00 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 0% | 189 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 724 | $0.00 |
| 86850 | 0% | 16 | $0.00 | |
| 87486 | 0% | 71 | $0.00 | |
| 96376 | 0% | 78 | $0.00 | |
| 86140 | 0% | 144 | $0.00 | |
| 82657 | 0% | 119 | $0.00 | |
| 0352U | 0% | 65 | $0.00 | |
| G0378 | Hospital observation service, per hour | 0% | 388 | $0.00 |
| 91315 | 0% | 31 | $0.00 | |
| 99153 | Mod sedat endo service >5yrs | 0% | 96 | $0.00 |
| 87581 | 0% | 71 | $0.00 | |
| 90716 | 0% | 12 | $0.00 | |
| 84703 | 0% | 14 | $0.00 | |
| 85730 | 0% | 14 | $0.00 | |
| 87040 | 0% | 13 | $0.00 | |
| 86901 | 0% | 17 | $0.00 | |
| 85018 | 0% | 13 | $0.00 | |
| 90696 | 0% | 25 | $0.00 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 27 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 470 | $0.00 |
| C1729 | Catheter, drainage | 0% | 218 | $0.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 105 | $0.00 |
| 90710 | 0% | 26 | $0.00 | |
| 90633 | 0% | 581 | $0.00 | |
| 90473 | 0% | 29 | $0.00 | |
| A4617 | Mouth piece | 0% | 402 | $0.00 |
| 87400 | 0% | 889 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 124 | $0.00 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 112 | $0.00 |
| 84702 | 0% | 16 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 14 | $0.00 |
| 80076 | 0% | 81 | $0.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 27 | $0.00 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 71 | $0.00 |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | 0% | 14 | $0.00 |
| 90700 | 0% | 27 | $0.00 | |
| 86900 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialALLEN, PATRICIA (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.